Nadege Gunn, MD

Gunn described her reaction to the SYNCHRONIZE-1 liver fat reduction data as genuinely compelling from a hepatology perspective, noting a reduction of up to 63% represents a level of hepatic fat clearance that could meaningfully transform the disease trajectory for patients, with the data also demonstrating reductions in non-invasive markers of fibrosis such as ELF and Pro-C3, adding further weight to the possibility that this combination could address not just fat accumulation but the fibrotic progression that drives the most serious liver-related morbidity.

Gunn explained the scientific rationale for combining GLP-1 and glucagon receptor agonism in the context of MASH, noting that the liver contains glucagon receptors, making the combination a compelling strategy for achieving more direct hepatic targeting than GLP-1 receptor agonism alone can provide.

This episode, titled 'Risk Stratification and Weight Loss as Therapy: A Hepatologist's Framework for Managing MASH Progression,' features Nadege Gunn, MD discussing the following critical questions: 1. How do you risk-stratify your patients, and what clinical or metabolic factors most reliably predict progression? 2. What does the literature tell us about the relationship between meaningful weight loss and fibrosis regression, and how does that inform your thinking about weight-loss therapy as a hepatic intervention?

In 'Screening MASH Upstream: Building a Practical, Scalable Algorithm for the Real World,’ Nadege Gunn, MD delves into the following critical question: 1. There is growing interest in screening for MASH further upstream. What would a practical, scalable screening algorithm look like in your view, and what are the limitations of that approach?

In this episode, 'Screening, Risk Stratification, and the Multidisciplinary Care Model for MASH,' the hepatologist Nadege Gunn, MD explores the following questions: 1. How would you characterize the urgency of MASH as a public health problem for a primary care physician who may see the early signs? 2. In an ideal world, what does the multidisciplinary care model for a MASH patient with significant obesity look like? How far is current clinical practice from that ideal, and where do the current gaps exist?

Welcome back to another AJMC Insights series. In this episode titled, 'MASH in Focus: How Patient Awareness, Clinical Empowerment, and Research Have Transformed the Field,' Nadege Gunn, MD led the conversation about the following questions: 1. As a hepatologist, how has the MASH patient population changed over the last decade? 2. Do you feel the broader medical community has kept pace with that shift? 3. How much of your current liver disease caseload would you attribute to metabolic and obesity-driven disease versus other etiologies?